FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026992024> ?p ?o ?g. }

• W2026992024 endingPage "231" @default.
• W2026992024 startingPage "221" @default.
• W2026992024 abstract "Forty-eight percent of somatic symptoms encountered in the primary care setting are medically unexplained. Such symptoms have been associated with negative impact on quality of life and with functional impairment.The aim of this study was to assess the potential utility and tolerability of paroxetine for the treatment of undifferentiated somatoform disorder (USD), using the 15-item Patient Health Questionnaire (PHQ-15) to assess the severity of somatic symptoms.A prospective, open-label, 8-week pilot study of paroxetine was conducted in outpatients with USD. Data were collected at baseline and at weeks 1, 2, 4, and 8. The primary measure was the mean change in PHQ-15 total score from baseline to the end of treatment. Secondary effectiveness measures included mean changes in total scores on the Beck Depression Inventory (BDI) and the 12-item General Health Questionnaire from baseline to end of treatment. A physical examination, electrocardiography, complete blood count, blood chemistry, urinalysis, and pregnancy test (for women of childbearing potential) were performed at baseline and the end of treatment. Vital signs were measured during each visit. Adverse events (AEs) were recorded during the study and included those determined using the Systematic Assessment for Treatment Emergent Events-General Inquiry.Forty-three Korean patients were screened for the study. Twenty-two patients (13 women, 9 men; mean [SD] age, 37.4 [12.4] years) were enrolled and 20 completed the study; 2 patients were lost to follow-up. The mean total score on the PHQ-15 from baseline to the end of treatment was significantly decreased (17.2 vs 4.3; P = 0.001), as was the mean total BDI score (12.8 vs. 6.3; P < 0.001). Overall, paroxetine was well-tolerated. Nausea and dry mouth were the most commonly reported treatment-emergent AEs (both, 5 [22.7%]); no serious AEs were reported. No abnormal laboratory results were observed.This open-label pilot study found that paroxetine had potential utility in the treatment of USD and was generally well-tolerated. These results suggest that adequately-powered, double-blind, placebo-controlled trials are warranted to more fully assess the efficacy and safety of paroxetine in the treatment of USD." @default.
• W2026992024 created "2016-06-24" @default.
• W2026992024 creator A5017929593 @default.
• W2026992024 creator A5025984426 @default.
• W2026992024 creator A5041007677 @default.
• W2026992024 creator A5054681325 @default.
• W2026992024 creator A5066746850 @default.
• W2026992024 creator A5083047501 @default.
• W2026992024 creator A5090592931 @default.
• W2026992024 creator A5091293337 @default.
• W2026992024 date "2008-06-01" @default.
• W2026992024 modified "2023-09-28" @default.
• W2026992024 title "Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study" @default.
• W2026992024 cites W101910072 @default.
• W2026992024 cites W1826161993 @default.
• W2026992024 cites W184125304 @default.
• W2026992024 cites W1968950664 @default.
• W2026992024 cites W1982752702 @default.
• W2026992024 cites W1999475508 @default.
• W2026992024 cites W2001878574 @default.
• W2026992024 cites W2022778601 @default.
• W2026992024 cites W2026973648 @default.
• W2026992024 cites W2036851003 @default.
• W2026992024 cites W2040309940 @default.
• W2026992024 cites W2041384275 @default.
• W2026992024 cites W2049695349 @default.
• W2026992024 cites W2054517429 @default.
• W2026992024 cites W2067495470 @default.
• W2026992024 cites W2082452224 @default.
• W2026992024 cites W2085009106 @default.
• W2026992024 cites W2085565936 @default.
• W2026992024 cites W2107031757 @default.
• W2026992024 cites W2126191204 @default.
• W2026992024 cites W2152620642 @default.
• W2026992024 cites W2156104108 @default.
• W2026992024 cites W2316878322 @default.
• W2026992024 cites W2397083761 @default.
• W2026992024 cites W2404833579 @default.
• W2026992024 cites W2415537520 @default.
• W2026992024 cites W2415726335 @default.
• W2026992024 cites W281463163 @default.
• W2026992024 cites W640994583 @default.
• W2026992024 cites W65047624 @default.
• W2026992024 cites W2130269157 @default.
• W2026992024 doi "https://doi.org/10.1016/j.curtheres.2008.06.004" @default.
• W2026992024 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3969909" @default.
• W2026992024 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24692800" @default.
• W2026992024 hasPublicationYear "2008" @default.
• W2026992024 type Work @default.
• W2026992024 sameAs 2026992024 @default.
• W2026992024 citedByCount "0" @default.
• W2026992024 crossrefType "journal-article" @default.
• W2026992024 hasAuthorship W2026992024A5017929593 @default.
• W2026992024 hasAuthorship W2026992024A5025984426 @default.
• W2026992024 hasAuthorship W2026992024A5041007677 @default.
• W2026992024 hasAuthorship W2026992024A5054681325 @default.
• W2026992024 hasAuthorship W2026992024A5066746850 @default.
• W2026992024 hasAuthorship W2026992024A5083047501 @default.
• W2026992024 hasAuthorship W2026992024A5090592931 @default.
• W2026992024 hasAuthorship W2026992024A5091293337 @default.
• W2026992024 hasBestOaLocation W20269920241 @default.
• W2026992024 hasConcept C118552586 @default.
• W2026992024 hasConcept C126322002 @default.
• W2026992024 hasConcept C139719470 @default.
• W2026992024 hasConcept C159110408 @default.
• W2026992024 hasConcept C162324750 @default.
• W2026992024 hasConcept C1862650 @default.
• W2026992024 hasConcept C188816634 @default.
• W2026992024 hasConcept C197934379 @default.
• W2026992024 hasConcept C2776867660 @default.
• W2026992024 hasConcept C2777828372 @default.
• W2026992024 hasConcept C2778375690 @default.
• W2026992024 hasConcept C2778529449 @default.
• W2026992024 hasConcept C2779177272 @default.
• W2026992024 hasConcept C2779225474 @default.
• W2026992024 hasConcept C2779631380 @default.
• W2026992024 hasConcept C2779951463 @default.
• W2026992024 hasConcept C2780026642 @default.
• W2026992024 hasConcept C2780051608 @default.
• W2026992024 hasConcept C2780733359 @default.
• W2026992024 hasConcept C2781161787 @default.
• W2026992024 hasConcept C3019858935 @default.
• W2026992024 hasConcept C558461103 @default.
• W2026992024 hasConcept C71924100 @default.
• W2026992024 hasConceptScore W2026992024C118552586 @default.
• W2026992024 hasConceptScore W2026992024C126322002 @default.
• W2026992024 hasConceptScore W2026992024C139719470 @default.
• W2026992024 hasConceptScore W2026992024C159110408 @default.
• W2026992024 hasConceptScore W2026992024C162324750 @default.
• W2026992024 hasConceptScore W2026992024C1862650 @default.
• W2026992024 hasConceptScore W2026992024C188816634 @default.
• W2026992024 hasConceptScore W2026992024C197934379 @default.
• W2026992024 hasConceptScore W2026992024C2776867660 @default.
• W2026992024 hasConceptScore W2026992024C2777828372 @default.
• W2026992024 hasConceptScore W2026992024C2778375690 @default.
• W2026992024 hasConceptScore W2026992024C2778529449 @default.
• W2026992024 hasConceptScore W2026992024C2779177272 @default.
• W2026992024 hasConceptScore W2026992024C2779225474 @default.

• next